The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient

Based on introduction of systemic treatment in an early stage and increasing numbers of HCC cases with a nonviral etiology, the positive rate of AFP level has been declining. Thus, determination of DCP and AFP-L3 in addition to AFP as markers should be more actively utilized in clinical practice, as well as clinical trials for monitoring and evaluating treatment response in this era of combination immunotherapy as a powerful treatment.

Authors

Institutions

Publication Details

Journal
Oncology
Published
2025-02-03
DOI
https://doi.org/10.1159/000543405
Citations
2
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
2.64
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient

Hideko Ohama, Norio Itokawa, Joji Tani, Kazunari Tanaka et al.
2 citations
Oncology
Hepatocellular Carcinoma Treatment and Prognosis
2.64
article

The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient

Hideko Ohama, Norio Itokawa, Joji Tani, Kazunari Tanaka, Yuki Kanayama, Tomomitsu Matono, Hidenao Noritake, Kazuhito Kawata, Kazuya Kariyama, Hidenori Toyoda, Hirayuki Enomoto, Kazuhiro Nouso, Takeshi Hatanaka, Masatoshi Kudo, Yoichi Hiasa, Kunihiko Tsuji, Atsushi Hiraoka, Takashi Kumada, Yoshiko Nakamura, Shinya Fukunishi, Tomomi Okubo, Takuya Nagano, Ei Itobayashi, Masaki Kaibori, Masashi Hirooka, Chikara Ogawa, Hiroki Nishikawa, Hisashi Kosaka, Kazuto Tajiri, Takashi Nishimura, Toshifumi Tada, Atsushi Naganuma, Akemi Tsutsui, Hidekatsu Kuroda, Toru Ishikawa, Yutaka Yata, Masanori Atsukawa, Yuichi Koshiyama, Tomoko Aoki, Fujimasa Tada, Asahiro Morishita, Koichi Takaguchi, Michitaka Imai, Satoru Kakizaki, Shinichiro Nakamura, Hironori Tanaka, Osamu Yoshida, Taeang Arai
article en
2 citations

Abstract

Based on introduction of systemic treatment in an early stage and increasing numbers of HCC cases with a nonviral etiology, the positive rate of AFP level has been declining. Thus, determination of DCP and AFP-L3 in addition to AFP as markers should be more actively utilized in clinical practice, as well as clinical trials for monitoring and evaluating treatment response in this era of combination immunotherapy as a powerful treatment.

OncologyVol. 104(1)
Kansai Medical University (JP), Iwate Medical University (JP), Kagawa University (JP), Hamamatsu University School of Medicine (JP), Takamatsu Red Cross Hospital (JP), Saiseikai Niigata Daini Hospital (JP), National Hospital Organization Takasaki Medical Center (JP), Okayama Prefecture (JP), Ogaki Municipal Hospital (JP), Himeji Medical Center (JP), Hanwa Memorial Hospital (JP), Gunma Saiseikai Maebashi Hospital (JP), Himeji Red Cross Hospital (JP), Teine Keijinkai Hospital (JP), Asahi General Hospital (JP), Toyama University Hospital (JP), Ehime Prefectural Central Hospital (JP), Kagawa Prefectural Central Hospital (JP), Takarazuka City Hospital (JP), Ehime University (JP), Gifu Kyoritsu University (JP), Nippon Medical School (JP), Hyogo University (JP), Osaka University of Pharmaceutical Sciences (JP), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 13%
Hepatocellular Carcinoma Treatment and Prognosis
2.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.